Nutriband Inc. has filed a new non-provisional patent application with the USPTO to strengthen intellectual property protection for its AVERSA™ transdermal abuse deterrent technology, used in opioid and stimulant patches. This technology uses a proprietary aversive agent coating to prevent abuse and accidental exposure. If granted, the patent could extend protection for AVERSA™-based products, such as AVERSA™ FENTANYL, potentially until 2046. The technology aims to improve the safety of transdermal drugs prone to abuse while maintaining patient access.
Nutriband's patent application for its transdermal abuse deterrent technology is presented here with Pluang's health sector market data as context. Among 100 health-sector US stocks priced on Pluang as of Oct 08, 2026 18:11 WIB, only 25 rose while 68 fell. Sana Biotechnology Inc (SANA) gained 2.94% with 73% buy orders and a typical hold time of 23 days, contrasting with Recursion Pharmaceuticals Inc (RXRX) which dropped 2.81% and saw 95% sell orders, and Heron Therapeutics Inc (HRTX) down 2.56% but with 70% buy orders and a longer hold time of 35 days.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Heineken N.V. has repurchased a total of 9,510,681 shares under the second tranche of its €1.5 billion share buyback program, spending €679.2 million as of October 30, 2026. The company bought 159,700 shares on the exchange and 160,530 shares from He...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
Alvotech, a global biotech company specializing in biosimilar medicines, announced its management team will participate in several investor conferences throughout November 2026. These include events in London, Oslo, and Stockholm, featuring presentat...
Alvotech, a global biotechnology company specializing in biosimilar medicines, will participate in four international investor conferences in November held in the UK, Norway, and Sweden. These events include presentations and analyst discussions host...
